Nyrada Inc Investor Presentation September 2024

› Drug discovery and development company specialising in rational design of novel small molecule therapeutics.

› Nyrada’s lead drug candidate NYR-BI03:

› demonstrated strong preclinical efficacy protecting the brain from secondary injury.

› currently undergoing Good Laboratory Practice safety and tolerability testing.

› preclinical TBI efficacy study with Walter Reed Army Institute of Research and UNSW in progress.

› Exploratory works for other indications and opportunities

› Commercially focused business model and expert team.